Protagonist Therapeutics (NASDAQ: PTGX) reported Q3 EPS of ($0.62), $0.01 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $4.71 million versus the consensus estimate of $4.51 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.